An extract of phase II and III trials on recent developments in managing neuropathic pain syndromes: diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia
Expert Opin Emerg Drugs. 2024 Feb 27. doi: 10.1080/14728214.2024.2323193. Online ahead of print.ABSTRACTINTRODUCTION: Neuropathic pain (NP) conditions involve lesions to the somatosensory nervous system leading to chronic and debilitating pain. Many patients suffering from NP utilize pharmacological treatments with various drugs that seek to reduce pathologic neuronal states. However, many of these drugs show poor efficacy as well as cause significant adverse effects. Because of this, there is a major need for the development of safer and more efficacious drugs to treat NP.AREAS COVERED: In this review, we analyzed current...
Source: Expert Opinion on Emerging Drugs - February 27, 2024 Category: Drugs & Pharmacology Authors: William C Upshaw Lenise G Soileau Nicholas R Storey Kassady A Perkinson Patrick M Luther Noah J Spillers Christopher L Robinson Cole Miller Shahab Ahmadzadeh Omar Viswanath Sahar Shekoohi Alan D Kaye Source Type: research
Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention
Expert Opin Emerg Drugs. 2024 Feb 9:1-8. doi: 10.1080/14728214.2024.2317778. Online ahead of print.ABSTRACTINTRODUCTION: The pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) has emerged as a key mediator of migraine pathogenesis. PACAP-38 and its receptors are predominantly distributed in arteries, sensory and parasympathetic neurons of the trigeminovascular system. Phase 2 trials have tested human monoclonal antibodies designed to bind and inhibit PACAP-38 and the pituitary adenylate cyclase-activating polypeptide type I (PAC1) receptor for migraine prevention.AREAS COVERED: This review focuses on the sign...
Source: Expert Opinion on Emerging Drugs - February 10, 2024 Category: Drugs & Pharmacology Authors: Lanfranco Pellesi Messoud Ashina Paolo Martelletti Source Type: research
